Deformable Imaging Capability for the Radiation Therapy Oncology Group (RTOG) Consensus Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Lower Extremities

2011 ◽  
Vol 81 (2) ◽  
pp. S684-S685
Author(s):  
S.E. Finkelstein ◽  
A. Trotti ◽  
G.D. Letson ◽  
M. Russell ◽  
T.F. DeLaney ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Radiation Therapy Oncology Group ◽  
Lower Extremities ◽  
Oncology Group ◽  
Imaging Capability ◽  
Musculoskeletal Anatomy

Radiation Therapy Oncology Group (RTOG) Consensus Panel Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Extremities

2010 ◽  
Vol 78 (3) ◽  
pp. S612 ◽  
Author(s):  
S.E. Finkelstein ◽  
A. Trotti ◽  
G.D. Letson ◽  
J. Caracciolo ◽  
T.F. DeLaney ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group ◽  
Consensus Panel ◽  
Musculoskeletal Anatomy

scholarly journals Margin reduction from image guided radiation therapy for soft tissue sarcoma: Secondary analysis of Radiation Therapy Oncology Group 0630 results

2016 ◽  
Vol 6 (4) ◽  
pp. e135-e140 ◽  
Author(s):  
X. Allen Li ◽  
Xiaojian Chen ◽  
Qiang Zhang ◽  
David G. Kirsch ◽  
Ivy Petersen ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Radiation Therapy Oncology Group ◽  
Secondary Analysis ◽  
Oncology Group ◽  
Image Guided Radiation Therapy ◽  
Image Guided

scholarly journals Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial

2015 ◽  
Vol 33 (20) ◽  
pp. 2231-2238 ◽  
Author(s):  
Dian Wang ◽  
Qiang Zhang ◽  
Burton L. Eisenberg ◽  
John M. Kane ◽  
X. Allen Li ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase Ii Trial ◽  
Radiation Therapy Oncology Group ◽  
Target Volume ◽  
Oncology Group ◽  
Image Guided Radiation Therapy ◽  
Image Guided ◽  
Extremity Soft Tissue Sarcoma

Purpose We performed a multi-institutional prospective phase II trial to assess late toxicities in patients with extremity soft tissue sarcoma (STS) treated with preoperative image-guided radiation therapy (IGRT) to a reduced target volume. Patients and Methods Patients with extremity STS received IGRT with (cohort A) or without (cohort B) chemotherapy followed by limb-sparing resection. Daily pretreatment images were coregistered with digitally reconstructed radiographs so that the patient position could be adjusted before each treatment. All patients received IGRT to reduced tumor volumes according to strict protocol guidelines. Late toxicities were assessed at 2 years. Results In all, 98 patients were accrued (cohort A, 12; cohort B, 86). Cohort A was closed prematurely because of poor accrual and is not reported. Seventy-nine eligible patients from cohort B form the basis of this report. At a median follow-up of 3.6 years, five patients did not have surgery because of disease progression. There were five local treatment failures, all of which were in field. Of the 57 patients assessed for late toxicities at 2 years, 10.5% experienced at least one grade ≥ 2 toxicity as compared with 37% of patients in the National Cancer Institute of Canada SR2 (CAN-NCIC-SR2: Phase III Randomized Study of Pre- vs Postoperative Radiotherapy in Curable Extremity Soft Tissue Sarcoma) trial receiving preoperative radiation therapy without IGRT (P < .001). Conclusion The significant reduction of late toxicities in patients with extremity STS who were treated with preoperative IGRT and absence of marginal-field recurrences suggest that the target volumes used in the Radiation Therapy Oncology Group RTOG-0630 (A Phase II Trial of Image-Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity) study are appropriate for preoperative IGRT for extremity STS.

The radiation therapy oncology group soft tissue sarcoma registry

1979 ◽  
Vol 5 ◽  
pp. 87-88
Author(s):  
Steven Mann ◽  
William Caldwell ◽  
Thomas Griffin ◽  
Homer Russ ◽  
JoAnn Stetz
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group

Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514

2006 ◽  
Vol 24 (4) ◽  
pp. 619-625 ◽  
Author(s):  
William G. Kraybill ◽  
Jonathon Harris ◽  
Ira J. Spiro ◽  
David S. Ettinger ◽  
Thomas F. DeLaney ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Body Wall ◽  
Radiation Therapy Oncology Group ◽  
High Grade ◽  
Oncology Group ◽  
Single Institution ◽  
Experienced Grade ◽  
Disease Free

Purpose On the basis of a positive reported single-institution pilot study, the Radiation Therapy Oncology Group initiated phase II trial 9514 to evaluate its neoadjuvant regimen in a multi-institutional Intergroup setting. Patients and Methods Eligibility included a high-grade soft tissue sarcoma ≥ 8 cm in diameter of the extremities and body wall. Patients received three cycles of neoadjuvant chemotherapy (CT; modified mesna, doxorubicin, ifosfamide, and dacarbazine [MAID]), interdigitated preoperative radiation therapy (RT; 44 Gy administered in split courses), and three cycles of postoperative CT (modified MAID). Results Sixty-six patients were enrolled, of whom 64 were analyzed. Seventy-nine percent of patients completed their preoperative CT and 59% completed all planned CT. Three patients (5%) experienced fatal grade 5 toxicities (myelodysplasias, two patients; infection, one patient). Another 53 patients (83%) experienced grade 4 toxicities; 78% experienced grade 4 hematologic toxicity and 19% experienced grade 4 nonhematologic toxicity. Sixty-one patients underwent surgery. Fifty-eight of these were R0 resections, of which five were amputations. There were three R1 resections. The estimated 3-year rate for local-regional failure is 17.6% if amputation is considered a failure and 10.1% if not. Estimated 3-year rates for disease-free, distant–disease-free, and overall survival are 56.6%, 64.5%, and 75.1%, respectively. Conclusion This combined-modality treatment can be delivered successfully in a multi-institutional setting. Efficacy results are consistent with previous single-institution results.

Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (STS COG)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9001-9001 ◽  
Author(s):  
D. O. Walterhouse ◽  
J. L. Meza ◽  
R. B. Raney ◽  
J. Anderson ◽  
E. S. Wiener ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Primary Endpoint ◽  
Low Risk ◽  
Newly Diagnosed ◽  
Oncology Group ◽  
Free Survival

9001 Background: The STS COG defines patients with low-risk RMS as those with localized tumors of embryonal histology that occur in favorable sites or occur in unfavorable sites and are grossly resected. Intergroup Rhabdomyosarcoma Studies (IRS)-III (1984–1991) and -IV (1991–1997) found that these patients had a 5-year failure-free survival (FFS) of 83% and an overall survival of 95%. Methods: Two subsets were identified for the IRS-V low-risk RMS study (D9602) (1997–2004) based on the hypothesis that they required different treatment intensities to achieve similar excellent outcomes. Patients assigned to Subset A (Stage [Sg] 1 Group [Gp] I/IIA, Sg 1 Gp III orbit, Sg 2 Gp I) received VA (cumulative doses over 1 year of treatment: V: 54 mg/m2, A: 24 mg/kg) ± local RT. Patients assigned to Subset B (Sg 2 Gp IIB/C, Sg 1 Gp III non-orbit, Sg 2 Gp II, Sg 3 Gp I/II) received VA + C (C: 28.6 g/m2) ± RT. The RT dose was reduced to 36 Gy (instead of 41.4 Gy on IRS-IV) for Gp IIA patients and to 45 Gy (instead of 50.4 or 59.4 Gy on IRS-IV) for Gp III orbit patients. The primary endpoint was FFS. Results: Estimated 3-yr FFS was 89% (95% CI 84%, 93%) for Subset A (n=263) and 89% (95% CI 77%, 95%) for Subset B (n=79). Median follow-up was 2.9 years. Estimated 3-yr FFS was 80% (95% CI 64%, 89%; n=59) for patients with Sg 1 Gp IIA disease and 88% (95% CI 77%, 94%; n=76) for Gp III orbit disease. Conclusions: There is not evidence to suggest that outcome for these patients differs from outcomes observed in similar patients treated on IRS-III and IRS-IV. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document